HCA Healthcare, Inc. (NYSE:HCA – Get Free Report) SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares in the company, valued at $18,445,700. This trade represents a 6.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
HCA Healthcare Price Performance
Shares of NYSE:HCA opened at $342.96 on Friday. HCA Healthcare, Inc. has a 52 week low of $238.82 and a 52 week high of $417.14. The business has a fifty day simple moving average of $386.00 and a 200-day simple moving average of $357.03. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The company has a market cap of $86.87 billion, a P/E ratio of 15.40, a P/E/G ratio of 1.34 and a beta of 1.68.
HCA Healthcare Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date is Friday, December 13th. HCA Healthcare’s payout ratio is currently 11.85%.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of research firms have commented on HCA. Barclays dropped their price objective on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Leerink Partners lifted their price objective on shares of HCA Healthcare from $367.00 to $396.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Truist Financial boosted their price target on shares of HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Wolfe Research raised HCA Healthcare to a “strong-buy” rating in a research note on Thursday, August 29th. Finally, Oppenheimer upped their price target on shares of HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, HCA Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $385.00.
View Our Latest Research Report on HCA
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Featured Articles
- Five stocks we like better than HCA Healthcare
- ESG Stocks, What Investors Should Know
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Top-Performing Non-Leveraged ETFs This Year
- ETF Screener: Uses and Step-by-Step Guide
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.